Prophylactic evaluation of verubecestat on disease and symptom modifying effects in 5XFAD mice

Alzheimer’s disease (AD) is the most common form of dementia. Beta-secretase (BACE) inhibitors have been proposed as potential therapeutic interventions however initiating treatment once disease has significantly progressed has failed to effectively stop or treat disease. Whether BACE inhibition may have efficacy when administered prophylactically in the early stages of AD has been under-investigated. The present studies aimed to evaluate prophylactic treatment of the BACE inhibitor verubecestat in an AD mouse model using the NIA resources of the MODEL-AD Preclinical Testing Core (PTC) Drug Screening Pipeline. 5XFAD mice were administered verubecestat ad libitum in chow from 3-6 months of age, prior to the onset of significant disease pathology. Following treatment, in vivo imaging was conducted with 18F-AV45 and 18-FDG-PET/MRI, brain and plasma beta-amyloid (Aβ) were measured, and the clinical and behavioral characteristics of the mice were assessed and correlated with pharmacokinetic data. Prophylactic verubecestat treatment resulted in dose- and region-dependent attenuations of 18F-AV45 uptake in male and female 5XFAD mice. Plasma Aβ40 and Aβ42 were also dose-dependently attenuated with treatment.  Across the dose range evaluated, side effects including coat color changes and motor alterations were reported, in the absence of cognitive improvement or changes in 18F-FDG uptake.  Prophylactic treatment with verubecestat resulted in attenuated amyloid plaque deposition when treatment was initiated prior to significant pathology in 5XFAD mice.  At the same dose range effective at attenuating Aβ levels, verubecestat produced side-effects in the absence of improvements in cognitive function.  Taken together these data demonstrate the rigorous translational approaches of the MODEL-AD PTC for interrogating potential therapeutics and provide insight into the limitations of verubecestat as a prophylactic intervention for early-stage AD.